Tiotropium Bromide/Olodaterol as Maintenance Treatment for Patients with COPD

Abstract

Chronic obstructive pulmonary disease (COPD) requires appropriate treatment regimens, since it is a major cause of morbidity and mortality worldwide. Recently, several clinical trials confirmed that compared with tiotropium monotherapy and combination therapy of long-acting β2 agonist (LABA) plus inhaled corticosteroids (ICSs), maintenance therapy with once-daily dosing of a fixed-dose combination (FDC) of tiotropium plus olodaterol was safe and effective in improving the lung function, associated symptoms, and health status of patients with moderate to very severe COPD. Overall, tiotropium plus olodaterol FDC should be considered as an option for maintenance therapy in patients with moderately severe and severe COPD. Further studies will be required to show the effectiveness of this FDC in preventing COPD exacerbations and as maintenance therapy in patients with asthma–COPD overlap syndrome (ACOS).